Thus, targeting the CXCL13/CXCR5/ERK/TNF-α and IL-1β pathway in the TG may provide a novel therapeutic approach for the treatment of the trigeminal neuralgia. The gene discussed is CXCL13; the disease is trigeminal neuralgia.